Abstract
Helicobacter pylori infection has been indicated as the main pathogenic factor in the development of chronic gastritis, peptic ulcer disease, and gastric malignancies. Although the vast majority of infected subjects do not carry but a mild, asymptomatic gastritis, still there are some cases in which the eradication of the infection appears mandatory. This review addresses current anti-Helicobacter regimens and pharmacological resources, and highlights the pros and cons of each of them, according to the most recent and reliable clinical trials. Also, basic recommendations are given, regarding treatment choice in the event of the failure of a first or second line eradicating strategy, and about the implementation of standard regimens with newer antibacterial devices as probiotics.
PMID: 15720247 [PubMed - indexed for MEDLINE]
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 375-384 |
| Numero di pagine | 10 |
| Rivista | Current Medicinal Chemistry |
| Stato di pubblicazione | Pubblicato - 2005 |
Keywords
- helicobacter pylori
Fingerprint
Entra nei temi di ricerca di 'Treatment of H. pylori infection: a review.'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver